Our Blog

Welcome to the CERES Regulatory Services blog! Here, you’ll find a wide range of articles and resources on Accelerated Approval Pathways and FDA Fast Track Designation, FDA Breakthrough Therapy Designation, FDA Priority Review Designation, FDA Approval Process, Regulatory Strategy for Therapeutics (Drugs, Biologics, Vaccines, Medical Devices, Cell and Gene Therapy and Advanced Tissue Products), Nonclinical Development, Clinical Development, FDA Meetings, Drug Development Pathways, Expedited Drug Approval, Innovative Therapies Development, NDA and BLA Submission Strategies, FDA Regulatory Guidance, FDA Accelerated and Expedited programs and Strategies of Interest to the Regulatory Scientist.

The Rinvoq Resubmission Journey: From FDA CRL to Approval 

Categories: Regulatory Rescue
The Rinvoq Resubmission Journey: From FDA CRL to Approval

Hello Regulatory Scientists, 

Today, let’s dive into the journey of Rinvoq (upadacitinib) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. 

Regulatory History and Initial Submission 

Drug: Rinvoq (upadacitinib) 
Mechanism of Action: Janus kinase (JAK) inhibitor, which helps reduce inflammation by blocking specific enzymes involved in the inflammatory process 
Indication: Treatment of moderate to severe rheumatoid arthritis 
Initial Submission Date: December 2018 

The Complete Response Letter (CRL) 

CRL Date: June 2019 
CRL Concerns: 

  1. Safety Profile: The FDA raised concerns about the safety profile, particularly related to thromboembolic events and other adverse effects. 
  1. Additional Data Requirements: Request for more detailed analyses and long-term safety data to better understand the risk profile. 
  1. Risk Management Plan: Need for a detailed risk management plan to monitor and mitigate potential adverse effects. 

Resubmission Strategy 

AbbVie, the company behind Rinvoq, implemented a comprehensive strategy to address the FDA’s concerns: 

  1. Enhanced Safety Monitoring: Provided additional long-term safety data and analyses, focusing on thromboembolic events and other adverse effects. 
  1. Detailed Risk Management Plan: Developed a robust risk management plan, including detailed monitoring guidelines and patient education materials. 
  1. Continuous FDA Engagement: Maintained open lines of communication with the FDA to ensure alignment on the resubmission strategy and clarify any outstanding questions. 

Resubmission Date: August 2019 

Outcome 

Approval Date: August 2019 
Rinvoq was approved for the treatment of moderate to severe rheumatoid arthritis, providing a new option for patients who have had an inadequate response or intolerance to methotrexate. 

Lessons Learned 

The journey of Rinvoq from CRL to approval highlights several key lessons for drug developers: 

  1. Robust Safety Data: Ensuring comprehensive long-term safety data is crucial to addressing FDA concerns and demonstrating the drug’s safety profile. 
  1. Effective Risk Management: Developing and implementing a detailed risk management plan can help mitigate potential adverse effects and ensure patient safety. 
  1. Continuous FDA Engagement: Maintaining open and ongoing communication with the FDA helps align development efforts with regulatory expectations. 
  1. Proactive Data Analysis: Providing thorough and detailed analyses of safety data can help address specific concerns raised by the FDA. 

Relevance for Current Drug Developers 

For companies developing drugs today, the Rinvoq case underscores the importance of strategic planning and meticulous data collection in the regulatory process. Here are some takeaways to help avoid a CRL and achieve first-cycle approval: 

  1. Thorough Pre-Submission Preparation: Ensure that all aspects of your submission, including safety data and risk management plans, meet FDA standards. 
  1. Proactive Risk Management: Identify and address potential risks early in the development process to prevent issues from arising during FDA review. 
  1. Engage with the FDA Early and Often: Regular interactions with the FDA can provide valuable guidance and help steer the development process. 
  1. Invest in Quality Data: Prioritize the collection of high-quality, detailed safety and efficacy data to support the submission. 
  1. Utilize Advisory Committees: Seek feedback from advisory committees to validate data and address potential concerns, even if formal hearings are not required. 

By learning from the Rinvoq resubmission experience, current drug developers can better navigate the regulatory landscape, avoid common pitfalls, and increase the likelihood of a successful first review cycle approval. 

Stay diligent and strategic, 

CERES Regulatory Services 

Picture of Asad Khan
Asad Khan